Dogwood Therapeutics (NASDAQ:DWTX) Releases Earnings Results

Dogwood Therapeutics (NASDAQ:DWTX) posted its quarterly earnings results on Thursday. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.20), FiscalAI reports.

Dogwood Therapeutics Stock Performance

Shares of NASDAQ DWTX traded down $0.01 during midday trading on Friday, hitting $1.97. 6,508 shares of the stock traded hands, compared to its average volume of 76,362. The firm has a market capitalization of $66.25 million, a P/E ratio of -0.19 and a beta of 1.71. Dogwood Therapeutics has a one year low of $1.28 and a one year high of $9.50. The firm has a 50-day moving average of $1.56 and a two-hundred day moving average of $2.04.

Analyst Upgrades and Downgrades

Several research firms recently commented on DWTX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Friday, July 24th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Dogwood Therapeutics in a research note on Tuesday, May 19th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Dogwood Therapeutics presently has a consensus rating of “Hold” and an average target price of $12.00.

Institutional Trading of Dogwood Therapeutics

An institutional investor recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP bought a new position in Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 9.05% of the stock is owned by hedge funds and other institutional investors.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.